Wainberg Weighs In on Advances in HER2+ GI Cancers

Partner | Cancer Centers | <b>UCLA Health Jonsson Comprehensive Cancer Center</b>

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Zev A. Wainberg, MD, an associate professor of medicine and surgery in the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), co-director of the UCLA Gastrointestinal Oncology Program, and director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center, to discuss his approach to treatment selection for patients with HER2-positive gastrointestinal malignancies.

In our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more!

Editor's note: This interview was conducted prior to the May 5, 2021 FDA approval of pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma based on findings from the KEYNOTE-811 trial.